![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 42.50 | 42.00 | 43.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0449 | -9.47 | 30.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/5/2024 21:17 | Ahhhhh…… That makes total sense……& | ![]() wolfoffoolstreets | |
26/5/2024 21:05 | Quick one Wolfie boy…… You just said you’ve seen off Thoth.. workinginpharma...ah But your profile says: “Wolfofwallstr Member since: 10 Jan 2024” Wanna explain that one?? | ![]() wolfoffoolstreets | |
26/5/2024 21:01 | That's great fake wolfie.. You did disappear for a wee while tho... We can be like jack and rose.. Watching the titanic sink together.. X | ![]() wolfofwallstreets | |
26/5/2024 21:00 | No worries. I’m not aiming to silence you…… And then when you slagged off Sareum Investors for poor spelling followed by copious posts with your bad spelling and grammar. Whilst your here, I’ll be here 😊 | ![]() wolfoffoolstreets | |
26/5/2024 20:38 | What’s a “plaus on words”? | ![]() wolfoffoolstreets | |
26/5/2024 19:52 | Ahhhh single are you? Makes sense. | ![]() wolfoffoolstreets | |
26/5/2024 19:48 | As well as the fact that your husband probably doesn’t want to go for a walk with you Wolfie. | ![]() wolfoffoolstreets | |
26/5/2024 19:46 | “I think if you truly were doing that well from sareum.. You wouldn't really have the time or the desire to come on a backwater BB like advfn to share that...you'd be off enjoying the Sunday afternoon of a bank holiday weekend..” Ahhhhh - that explains why you are on shift 24/7 on here then. Makes complete sense. | ![]() wolfoffoolstreets | |
26/5/2024 15:02 | Some great positive news there on lse... Some lovely ramping material.. There's always good news...or an update.. or a new patent... But it never actually does anything. | ![]() wolfofwallstreets | |
26/5/2024 13:53 | Darkpoo... I think if you truly were doing that well from sareum.. You wouldn't really have the time or the desire to come on a backwater BB like advfn to share that...you'd be off enjoying the Sunday afternoon of a bank holiday weekend.. But..that's true of all the sareum LTHs isn't it.. We've all done well..made millions..free carry etc... | ![]() wolfofwallstreets | |
25/5/2024 21:28 | Just fo you troll. Literally fo. | ![]() criticalthinker1 | |
25/5/2024 20:23 | Another long boring copy and paste post from criticalstinker... 😴 I didn't read it. Guaranteed nobody else does either.. | ![]() wolfofwallstreets | |
25/5/2024 20:17 | Re 1801 this from 2023 ..oh how we have come on 4.5. SAR-20347 SAR-20347 is an oral inhibitor of Tyk2 and Jak1 with selectivity over Jak2 and Jak3. Preclinical assays demonstrated that SAR-20347 inhibited IL-12, IL-23 and IFN-α signaling [22]. Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22]. Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22]. The bodies in 'control' of certain narratives know full well what Sareum is undertaking. This is going to make Novacyt huge rise look like a blip. 1802 is going to be on the tail end and the results of 1801 will be very significant in its future All best Steadydanny | ![]() criticalthinker1 | |
25/5/2024 19:34 | Abilitylesswyth... It's a lot of money for most normal people... But not the millionaire LTHs of sareum...it's probably old thoths family honouring his memory by buying some shares... I dont think there will be an rns on Tuesday... More happy clappy ramping nonsense... I do believe the next rns will not be good for sareum.. | ![]() wolfofwallstreets | |
25/5/2024 19:22 | So the big question is really ... Who would spend £100K on SAR on a Friday ? Not a normal investor as that's a load a dosh ;Me thinks positive news is due very soon as no one would simply take a punt with £100k My guess ... will be smelling those lovely shorts burning some time next week The underdogs are moving forwards .. a bit like the match today, not that I support either but nice to see City not winning everything Did you guys watch it or were you sitting on this BB ALL DAY ? Toodle pip ... will log back in on Tuesday .. hopefully to a jolly nice RNS and the smell of burning shorts | ![]() aberystwyth |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions